Join us as we look back at the highly anticipated 4th instalment of the Pharmaceutical Industry and Regulators Symposium, held at the prestigious Auditório do Conselho Federal de Farmácia in Brasilia. Packed to capacity, this event was a resounding success, attracting industry experts and regulatory authorities across Brazil.
What is the Pharmaceutical Industry and Regulators Symposium?
Each year, the symposium brings together experts from the pharmaceutical industry and regulatory bodies to address the latest trends and developments in the field. Supported by the Conselho Federal de Farmácia and Sindusfarma, this two-day event offered attendees a remarkable opportunity to engage in thought-provoking discussions centred around cutting-edge science and technologies employed to address regulatory requirements. The diversity of topics covered during the symposium ensured that all participants left with invaluable insights.
Lhasa Senior Application Scientist, Margarita Munoz-Henao presenting at the symposium.
What our guests said about the event
Thássia De Oliveira, from Grupo FarmaBrazil attended the event, here’s what she had to say:
“The Pharmaceutical Industry and Regulators Symposium was a very rich experience, which integrated several areas related to impurities. Lhasa was able to show us the next steps and what is yet to come. The event was organised impeccably and featured great speakers. I hope to be present at future editions.”
Lhasa Senior Application Scientist, Gabriela Silveira; Principal Scientists, Mike Burns and David Ponting presenting at the symposium.
Dayvson Palmeira, from laboratório Cristália shared an insight into his experience:
“The 2023 Pharmaceutical Industry and Regulators Symposium offered an important platform for exchanging knowledge on cutting-edge regulatory topics, particularly regarding the control of impurities in drug substances and drug products.”
The agenda featured pioneering talks across a broad spectrum of key topics such as N-nitrosamines and the application of in silico tools for mutagenicity assessments.
“It was nice to witness the practical application of Lhasa’s in silico tools in mutagenic/genotoxic impurities risk analysis, especially the complementarity of these tools demonstrated through the presented case studies” – commented Davyson. “The presentations on strategies for controlling Nitrosamines Drug Substance Related Impurities (NDSRIs) were highly intriguing, particularly the recent advancements by Lhasa in the read-across approach.”
The Lhasa team at the symposium.
Keep an eye out for more information about next year’s symposium, we look forward to seeing you there! In the meantime, discover where you can find us next on our events page.
Last Updated on January 25, 2024 by lhasalimited
